Trial Profile
A Drug Interaction Study Investigating the Effect of Boceprevir on the Pharmacokinetics of the Calcium Channel Blockers Amlodipine and Diltiazem and Vice Versa in Healthy Volunteers
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs Boceprevir (Primary) ; Amlodipine; Diltiazem
- Indications Angina pectoris; Hepatitis C; Hypertension
- Focus Pharmacokinetics
- 08 Jan 2015 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
- 19 Mar 2012 New trial record